scholarly journals Modular Design of High-Brightness pH-Activatable Near-Infrared BODIPY Probes for Noninvasive Fluorescence Detection of Deep-Seated Early Breast Cancer Bone Metastasis: Remarkable Axial Substituent Effect on Performance

Author(s):  
Peng Wu ◽  
Yu Zhu ◽  
Senyao Liu ◽  
Hu Xiong
2018 ◽  
Author(s):  
Sofia Sousa ◽  
Evelyne Gineyts ◽  
Sandra Geraci ◽  
Martine Croset ◽  
Philippe Clézardin

ACS Nano ◽  
2017 ◽  
Vol 11 (7) ◽  
pp. 7259-7273 ◽  
Author(s):  
Han Qiao ◽  
Zhaowen Cui ◽  
Shengbing Yang ◽  
Dingkun Ji ◽  
Yugang Wang ◽  
...  

2008 ◽  
Vol 68 (S 01) ◽  
Author(s):  
C Schem ◽  
DO Bauerschlag ◽  
J Weimer ◽  
M Zhang ◽  
W Jonat ◽  
...  

2019 ◽  
Vol 19 (5) ◽  
pp. 667-676
Author(s):  
José R. Santin ◽  
Gislaine F. da Silva ◽  
Maria V.D. Pastor ◽  
Milena F. Broering ◽  
Roberta Nunes ◽  
...  

Background: It was recently demonstrated that the phthalimide N-(4-methyl-phenyl)-4- methylphthalimide (MPMPH-1) has important effects against acute and chronic pain in mice, with a mechanism of action correlated to adenylyl cyclase inhibition. Furthermore, it was also demonstrated that phthalimide derivatives presented antiproliferative and anti-tumor effects. Considering the literature data, the present study evaluated the effects of MPMPH-1 on breast cancer bone metastasis and correlated painful symptom, and provided additional toxicological information about the compound and its possible metabolites. Methods: In silico toxicological analysis was supported by in vitro and in vivo experiments to demonstrate the anti-tumor and anti-hypersensitivity effects of the compound. Results: The data obtained with the in silico toxicological analysis demonstrated that MPMPH-1 has mutagenic potential, with a low to moderate level of confidence. The mutagenicity potential was in vivo confirmed by micronucleus assay. MPMPH-1 treatments in the breast cancer bone metastasis model were able to prevent the osteoclastic resorption of bone matrix. Regarding cartilage, degradation was considerably reduced within the zoledronic acid group, while in MPMPH-1, chondrocyte multiplication was observed in random areas, suggesting bone regeneration. Additionally, the repeated treatment of mice with MPMPH-1 (10 mg/kg, i.p.), once a day for up to 36 days, significantly reduces the hypersensitivity in animals with breast cancer bone metastasis. Conclusion: Together, the data herein obtained show that MPMPH-1 is relatively safe, and significantly control the cancer growth, allied to the reduction in bone reabsorption and stimulation of bone and cartilage regeneration. MPMPH-1 effects may be linked, at least in part, to the ability of the compound to interfere with adenylylcyclase pathway activation.


Bone ◽  
2011 ◽  
Vol 48 ◽  
pp. S253 ◽  
Author(s):  
D.D. Lin ◽  
S.P. Pathi ◽  
C. Fischbach-Teschl ◽  
L.A. Estroff

Sign in / Sign up

Export Citation Format

Share Document